The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) unit in Pune, citing serious irregularities regarding the storage, packaging, and recall procedures for Reactin Plus Tablets, the regulatory body announced.
The licence cancellation took effect on August 27 following an inspection at the company's primary warehouse located in Wadki, Pune district, according to a statement released by the regulator on Friday.